Kaldirim H.Yazgan S.Kirgiz A.Kürşat A.Nacaroğlu Ş.A.2024-08-042024-08-0420201300-1256https://doi.org/10.37845/RET.VIT.2020.29.19https://hdl.handle.net/11616/91168Purpose: To evaluate the effectiveness of intravitreal injections of dexamethasone (DEX) implant in patients with pseudophakic cystoid macular edema (PCME) or Irvine-Gass Syndrome (IGS). Material and Methods: Patients with ME secondary to uncomplicated cataract surgery who underwent single intravitreal injections of DEX implant from January 2015 to January 2017 were retrospectively reviewed. The patients were examined at base-line and day 1, week 1, month 1, 3, 6 and 12 after intravitreal injection. All patients underwent a complete ophthalmic evaluation, including biomicroscopy, best-corrected visual acuity (BCVA), intraocular pressure by applanation tonometry, and central macular thickness (CMT) measurement with a spectral-domain optical coherence tomography (SD-OCT). Results: Nineteen eyes of 18 patients were evaluated. The alteration of mean BCVA and CMT were statistically significantly better than baseline values at first, third, sixth and twelfth months (p< 0.001). At 1st week, 1st month and 3rd month intraocular pressure (IOP) values significantly higher than baseline (p=0.001, p=0.006, p=0.001, respectively). At 6th month and 12th month IOP values not significantly different at baseline (p=0.506, p=0.650). Conclusion: Both BCVA and mean CMT had significantly improved from baseline values after treatment with single doz intravitreal DEX implant in patients with IGS. © 2020 Gazi Eye Foundation. All rights reserved.eninfo:eu-repo/semantics/closedAccessIntravitreal dexamethasone implantIrvine-gass syndromePseudophakic cystoid macular edemaArticle29210511010.37845/RET.VIT.2020.29.192-s2.0-85090849560Q4